Comparing two potassium-lowering heart failure drugs
Treatments studied
Part of Heart & circulation, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study compares two medicines, spironolactone and finerenone, to see which one manages potassium levels better in people with heart failure, type 2 diabetes, and kidney disease. Participants have high potassium levels, and the trial aims to find a safer way to manage this.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have a diagnosis of heart failure
- Have type 2 diabetes
- Have diabetic kidney disease (urine protein-to-creatinine ratio of 30 mg/g or more)
- Have moderately reduced to normal kidney function (eGFR at least 25)
- Have potassium level between 5.0 and 5.5 mEq/L at screening
- Not be pregnant or breastfeeding
- Not be taking other potassium-sparing diuretics
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called finerenone to see if it helps people hospitalized for heart failure live longer and have fewer heart-related problems. It may be an option for those with a certain type of heart failure where the heart's pumping strength is mildly reduced or normal.
This trial tests a medication called Finerenone to see if it can improve heart structure and function in people with both diabetic kidney disease and heart failure. If you have type 2 diabetes, kidney problems, and heart failure with preserved pumping function, this study may explore a new treatment option for you.
This trial tests a medication, finerenone, to help protect kidney function and prevent heart failure in people with type 2 diabetes and chronic kidney disease. If you have diabetes and kidney problems, this medicine might slow down further kidney damage.
This trial tests a new medicine called finerenone to see if it can reduce heart scarring and improve heart function in people with a certain type of heart failure (preserved ejection fraction). If you qualify, you may help researchers learn if this treatment can help you feel better and stay out of the hospital.
This study tests whether finerenone, a new type of drug, can help people with heart failure who cannot take standard steroid-based MRAs (a kind of heart medication) because of side effects or other reasons. It aims to see if it improves symptoms and is safe for you.
This trial studies whether a drug called finerenone can safely and effectively treat kidney disease caused by type 2 diabetes. If you qualify, you would take finerenone while your regular diabetes and blood pressure medications continue unchanged.
Hear when a new Heart failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.